European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
06 juin 2023 09h07 HE
|
ZyVersa Therapeutics
Cholesterol Transport Mediator™ VAR 200 is in development to reduce renal cholesterol and lipid accumulation that damages the kidneys' filtration system in patients with glomerular diseases, including...
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
25 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Juvenile idiopathic arthritis (“JIA”), a complex autoimmune inflammatory disorder, is the most common childhood chronic rheumatic diseaseThis is the first report documenting inflammasome activation in...
ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors
19 mai 2023 16h15 HE
|
ZyVersa Therapeutics
WESTON, Fla., May 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the...
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
15 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
12 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with renal...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
11 mai 2023 09h07 HE
|
ZyVersa Therapeutics
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
09 mai 2023 09h05 HE
|
ZyVersa Therapeutics
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and...
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
04 mai 2023 09h07 HE
|
ZyVersa Therapeutics
Prolonged systemic inflammation contributes to poor clinical outcomes in severe alcohol-associated hepatitis (“AH”) even after cessation of alcohol useReported data demonstrate a central role of NLRP3...
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
01 mai 2023 18h30 HE
|
ZyVersa Therapeutics
WESTON, Fla., May 01, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for...
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference
27 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Mr. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for numerous CNS...